請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23162
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳進庭 | |
dc.contributor.author | Yi-Chen Tsai | en |
dc.contributor.author | 蔡宜珍 | zh_TW |
dc.date.accessioned | 2021-06-08T04:45:07Z | - |
dc.date.copyright | 2009-08-18 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-03 | |
dc.identifier.citation | Avvisati G. Bortezomib plus melphalan and prednisone for multiple myeloma. N Engl J Med. 2008. 359(24):2613.
Baronzio G, Gramaglia A, Fiorentini G. Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. In Vivo. 2009. 23(1):143-146. Berk LB. Radiation therapy as primary and adjuvant treatment for local and regional melanoma. Cancer Control. 2008.15(3):233-238. Bonnin C, Trojani M, Corcuff JB, Bonichon F. Outcome of 111 thyroid papillary carcinomas. Retrospective study from 1953 to 1994. Experience of Bergonié InstituteAnn Endocrinol (Paris). 1997. 58(4):318-325. BS Yadav, SC Sharma. Orbital lymphoma: Role of radiation. Indian J Ophthalmol. 2009. 57(2):91-97. Chauhan A, Singh H, Sharma T, Manocha KK. Gemcitabine concurrent with radiation therapy for locally advanced head and neck carcinomas. Afr Health Sci. 2008. 8(3):149-55. Cole MP, Todd ID, Wilkinson PMA. preliminary trial of doxorubicin in advanced breast cancer and other malignant disease. Br J Cancer. 1974. 29(2):114-116. Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, Goldhirsch A, Veronesi A, Muss H. Breast cancer in the elderly. J Clin Oncol. 2007. 25(14):1882-1890. Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs. 2009;69(7):859-88. De Palo G. Cervical precancer and cancer, past, present and future. Eur J Gynaecol Oncol. 2004. 25(3):269-278. de Vathaire F. The carcinogenic effects of radioiodine therapy for thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008. 4(4):180-181. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003. 3:380-387. Dryl J. Results of cervical cancer treatment at the Lower Silesian Oncology Center between 1987 and 1989. Ginekol Pol. 2002. 73(12):1184-1191. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicit .Cardiovasc Hematol Agents Med Chem. 2008. 6(4):278-281. Fukaya T, Yoshida J, Banno T, Kageyama N, Ito M. Intracranial collision tumor--A case report (author's transl). No Shinkei Geka. 1976. 4(6):585-591. Golubicic I, Borojevic N, Pavlovic T. Risk factors for breast cancer: is ionizing radiation among them? J BUON. 2008. 13(4):487-494. Highley MS, Griffiths GO, Uscinska BM, Huddart RA, Barber JB, Parmar MK, Harper PG. A Phase II Trial of Continuous 5-Fluorouracil in Recurrent or Metastatic Transitional Cell Carcinoma of the Urinary Tract. Clin Oncol (R Coll Radiol). 2009. 21(5):394-400. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res. 1999. 5 (11):3645-3652. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992. 52(24):6774-6781. Janzen LA, Spiegler BJ. Neurodevelopmental sequelae of pediatric acute lymphoblastic leukemia and its treatment. Dev Disabil Res Rev. 2008. 14(3):185-195. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007. 4;298(1):70-82. Kelland LR. Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2005. 10(2):413-424. Keshelava N, Seeger RC, Reynolds CP. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur J Cancer. 1997. 33(12):2002-2006. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008. 14(3):354-377. Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol. 2007. 18 Suppl 6:vi70-3. Lu H, Yao M. The current status of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Cancer Treat Rev. 2008. 34(1):27-36. Markman M. Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin. Ther Clin Risk Manag. 2009. 5(1):161-168. Minisini AM, Andreetta C, Fasola G, Puglisi F. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert Rev Anticancer Ther. 2008. 8(3):331-342. Miyazaki J, Kawai K, Hayashi H, Onozawa M, Tsukamoto S, Miyanaga N, Hinotsu S, Shimazui T, Akaza H. The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer. Jpn J Clin Oncol. 2003. 33(8):391-395. Namiki Y, Namiki T, Date M, Yanagihara K, Yashiro M, Takahashi H. Enhanced photodynamic antitumor effect on gastric cancer by a novel photosensitive stealth liposome. Pharmacol Res. 2004. 50(1):65-76. Pandolfi C. Surgical and postsurgical therapy of differentiated carcinomas of the thyroid. Minerva Med. 1986. 77(28-29):1355-1357. Rafaniello Raviele P, Pruneri G, Maiorano E. Plasmablastic lymphoma: a review. Oral Dis. 2009. 15(1):38-45. Sasano H, Nagasaki S, Miki Y, Suzuki T. New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase. Ann N Y Acad Sci. 2009. 1155:76-79. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology. 2001. 61 Suppl 1:3-13. Sheng LM, Zhang LZ, Xu HM, Zhu Y. Ascending colon adenocarcinoma with tonsillar metastasis: a case report and review of the literature. World J Gastroenterol. 2008. 14(46):7138-7140. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to managemen.t Prog Cardiovasc Dis. 2007. 49(5):330-352. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005. 4(2):145-160. Uchegbu, Ijeoma F. Parenteral drug delivery: 1. Pharmaceutical Journal. 1999. 263: 309-318. Umansky F, Shoshan Y, Rosenthal G, Fraifeld S, Spektor S. Radiation-induced meningioma. Neurosurg Focus. 2008. 24(5):E7. van der Molen L, van Rossum MA, Burkhead LM, Smeele LE, Hilgers FJ. Functional outcomes and rehabilitation strategies in patients treated with chemoradiotherapy for advanced head and neck cancer: a systematic review. Eur Arch Otorhinolaryngol. 2009. 266(6):889-900. van Dalen EC, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev. 2009. (1): CD006325. Webber J, Leeson B, Fromm D, Kessel D. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor. J Photochem Photobiol B. 2005. 78(2):135-140. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23162 | - |
dc.description.abstract | 癌症是由細胞不正常複製、增生,所形成的惡性腫瘤組織,會入侵並破壞正常組織器官,甚至轉移至身體其他部位,導致患者死亡。目前常使用之化學治療方式,因無法只針對癌細胞進行專一毒殺,使用上會對患者造成副作用。所以科學家利用微脂體 (liposome) 能專一累積於腫瘤組織之特性,將化療藥物包覆其中,藉此改善化療藥物毒性;但由於包覆於微脂體中,但由於藥物釋放速度過慢,而使微脂體化療藥物治療癌症效果不如預期。而近期一種癌症治療方式—光動力治療,則是針對腫瘤部位,利用光感物質被特定波長光源激發,產生單態氧及自由基,造成腫瘤細胞死亡之治療模式。本篇研究即是想結合光動力治療及化學治療兩種方式,結合包在埋微脂體中的光感物質與化療藥物,以造成腫瘤毒殺外,達到加強腫瘤毒殺效果。本研究首先在細胞實驗中,確認微脂體藥物,有更好之細胞毒殺效果。而後在活體老鼠實驗中也發現,兩者之結合具有更好之抑制腫瘤生長效應,並延長老鼠之存活時間。 | zh_TW |
dc.description.abstract | Photodynamic therapy (PDT), which is based on the uptake of a photosensitizer followed by the selective irradiation of light, is a therapeutic modality for cancer treatment. Due to the limited light penetration, PDT is generally considered as a local treatment. To enhance the efficacy of cancer treatment, we prepared a polyethylene glycol (PEG) modified liposome simultaneously encapsulated with photosensitizer or chemotherapeutical drug. The cellular localization of these liposomes was in the cytoplasmic area only. To address the cytotoxicity of these liposomes, colony formation assay was performed after light irradiation. At the light dose of 20 J/cm2, 5 ng/ml of liposome drug can produce 40% cytotoxicity; however, the combined effect of liposome can produce over 80% cytotoxicity. Finally, we examined the anti-tumor efficacy of the liposome with C-26 syngeneic tumor model in BALB/cByJ mice | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T04:45:07Z (GMT). No. of bitstreams: 1 ntu-98-R96b47414-1.pdf: 2666822 bytes, checksum: 29e4fe58b55d3bfe653e691581b27ec7 (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 中文摘要-------------------------------------------------------------------------------------------- i
英文摘要------------------------------------------------------------------------------------------- ii 目錄------------------------------------------------------------------------------------------------- iii 縮寫表-----------------------------------------------------------------------------------------------iv 第一章 緒論 1.1 癌症及其治療方式--------------------------------------------------------------- P.1 1.2 Doxorubicin ----------------------------------------------------------------------- P.5 1.3 Liposomal-Doxorubicin --------------------------------------------------------- P.6 1.4 光動力治療 ----------------------------------------------------------------------- P.8 1.5 光感物質 ------------------------------------------------------------------------ P.11 1.6 研究動機與目的 --------------------------------------------------------------- P.12 第二章 材料與方法 2.1 藥物與儀器 --------------------------------------------------------------------- P.14 2.2 細胞株 --------------------------------------------------------------------------- P.16 2.3 細胞計數 ------------------------------------------------------------------------ P.17 2.4 微脂體製備-----------------------------------------------------------------------P. 18 2.5 光動力治療 --------------------------------------------------------------------- P.18 2.6 Ce6 uptake ----------------------------------------------------------------------- P.19 2.7 共軛焦顯微鏡 ------------------------------------------------------------------ P.19 2.8 細胞存活率檢測 --------------------------------------------------------------- P.20 2.9 細胞死亡型態檢測 ------------------------------------------------------------ P.22 2.10 活體動物實驗 ------------------------------------------------------------------ P.23 統計分析 ---------------------------------------------------------------------------------P.24 第三章 結果 3.1 雙效型微脂體光動力作用在細胞分子層次的研究 --------------------- P.25 3.2 雙效型微脂體光動力作用在活體動物實驗的應用 --------------------- P.32 第四章 討論 ---------------------------------------------------------------------------------- P.34 第五章 結論 ---------------------------------------------------------------------------------- P.39 Figure 1~12 ------------------------------------------------------------------------------------- P.41 附圖一至六------------------------------------------------------------------------------------- P.62 參考文獻 --------------------------------------------------------------------------------------- P.68 | |
dc.language.iso | zh-TW | |
dc.title | 雙效型微脂體用於抑制腫瘤生長之探討 | zh_TW |
dc.title | Investigation of dual-effect liposome
in inhibiting tumor growth | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡翠敏,鄧麗珍,黃慶璨,許瑞祥 | |
dc.subject.keyword | 光動力效應,Doxorubicin,Chlorin e6,雙效型微脂體, | zh_TW |
dc.subject.keyword | Photodynamic therapy,Chlorin e6,Doxorubicin,Dual-effect liposome, | en |
dc.relation.page | 70 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2009-08-03 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 微生物與生化學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 2.6 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。